Page last updated: 2024-12-06

selfotel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

selfotel: a N-methyl-D-aspartate (NMDA) antagonist; used to treat stroke-induced impairment [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68736
CHEMBL ID39664
CHEBI ID34973
SCHEMBL ID120234
MeSH IDM0151976

Synonyms (56)

Synonym
PDSP2_001471
NCGC00025070-01
selfotel
110347-85-8
selfotel (usan/inn)
D02410
selfotel [usan:inn]
cpdd 0027
2-piperidinecarboxylic acid, 4-(phosphonomethyl)-, cis-
cis-4-(phosphonomethyl)pipecolic acid
cgs-19755
cgs 19755
cpdd-0027
CHEMBL39664 ,
chebi:34973 ,
gnf-pf-157 ,
(2s,4r)-4-(phosphonomethyl)piperidine-2-carboxylic acid
4-phosphonomethyl-piperidine-2-carboxylic acid
4-phosphonomethyl-piperidine-2-carboxylic acid (cgs-19755, ly 272541)
bdbm50004927
cis-(+)-((2s,4r)-4-phosphonomethyl-piperidine-2-carboxylic acid
cis-4-(phosphonomethyl)piperidine-2-carboxylic acid
cas-110347-85-8
dtxcid3025675
tox21_110945
dtxsid5045675 ,
unii-4vgj4a41l2
4vgj4a41l2 ,
113229-62-2
2-piperidinecarboxylic acid, 4-(phosphonomethyl)-, (2r,4s)-
selfotel, (+)-
2-piperidinecarboxylic acid, 4-(phosphonomethyl)-, (2s,4r)-
cgs-20282
n0905w44y3 ,
unii-n0905w44y3
AKOS015914119
selfotel [who-dd]
selfotel [inn]
selfotel [usan]
cis-4-(phosphonomethyl)-2-piperidine carboxylic acid
selfotel [mart.]
2-piperidinecarboxylicacid, 4-(phosphonomethyl)-, (2r,4s)-rel-
gtpl4155
cgs19755
cis-4-(phosphonomethyl)-piperidine-2-carboxylic acid
SCHEMBL120234
(2s,4r)-4-(phosphonomethyl)-2-piperidinecarboxylic acid
cis-4-[phosphomethyl]-piperidine-2-carboxylic acid
cis-4-[phosphonomethyl]-piperidine-2-carboxylic acid
2-piperidinecarboxylicacid,4-(phosphonomethyl)-,(2r,4s)-rel-
cis-4-phosphonomethyl-2-piperidine carboxylic acid
Q7448341
C-310
(2s,4r)-4-(phosphonomethyl)piperidine-2-carboxylic acid.
D85721
cis-4-(phosphonomethyl)piperidine-2-carboxylicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In contrast, oxidized DTT did not enhance NMDA toxicity nor was it toxic when added alone."( The action of CGS-19755 on the redox enhancement of NMDA toxicity in rat cortical neurons in vitro.
Aizenman, E; Hartnett, KA, 1992
)
0.28
"5 mg/kg CGS 19755 is safe and tolerable in patients with acute ischemic stroke."( Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial.
Clark, W; Coull, B; Goldstein, LB; Grotta, J; LaRue, L; Mackay, B; Meissner, I; Murphy, D; Pettigrew, LC, 1995
)
0.53
"Recent clinical trials with non-competitive and competitive N-methyl-D-aspartate (NMDA) receptor antagonists in patients with stroke have shown that these patients develop more adverse effects, particularly psychomimetic effects such as hallucinations and agitation, than normal volunteers at equivalent doses."( Focal ischemia enhances the adverse effect potential of N-methyl-D-aspartate receptor antagonists in rats.
Löscher, W; Szabo, L; Wlaź, P, 1998
)
0.3
" No patient had severe adverse reactions."( Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients.
Bell, TE; Kotake, AN; Powell, M; Steinberg, GK; Yenari, MA,
)
0.36
" No consistent, serious, adverse events were considered to be due to drug effects, and death, in the one patient who died, was due to the effects of the injury."( First observations of the safety and tolerability of a competitive antagonist to the glutamate NMDA receptor (CGS 19755) in patients with severe head injury.
Bullock, R; Stewart, L; Teasdale, GM; Wagstaff, A, 1999
)
0.3
"5 mg/kg were shown to be safe in phase 1 and phase 2a studies."( Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist.
Albers, GW; Davis, SM; Diener, HC; Karlsson, G; Lees, KR; Markabi, S; Norris, J, 2000
)
1.75
" This was likely because of the fact that glutamate, now toxic at much lower concentrations, was able to reach and activate dendritic receptors under these conditions."( NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro.
Aizenman, E; Blitzblau, RC; Du, S; Leszkiewicz, DN; Rosenberg, PA; Sinor, JD; Venneti, S, 2000
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
" We report the protective effects of CGS-19755 (an N-methyl-D-aspartate receptor blocker), hypothermia or CGS-19755 in combination with mild hypothermia, in a gerbil model of repetitive ischemia."( CGS-19755 is neuroprotective during repetitive ischemia: this effect is significantly enhanced when combined with hypothermia.
Ijaz, S; Mazagri, R; Senthilsevlvan, A; Shuaib, A, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In dose-response studies, ifenprodil attenuated the NMDA-induced increase in medium GABA at all ages tested with an Imax of 10 microM."( Developmental differences in antagonism of NMDA toxicity by the polyamine site antagonist ifenprodil.
Nicklas, WJ; Zeevalk, GD, 1992
)
0.28
", allowing for better dosage control."( 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action.
Arnold, MB; Elzey, T; Leander, JD; Lodge, D; Ornstein, PL; Paschal, JW; Schoepp, DD, 1991
)
0.28
" CGS 19755 was studied using single and cumulative dosing procedures up to a dose of 10."( The competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 attenuates the rate-decreasing effects of NMDA in rhesus monkeys without producing ketamine-like discriminative stimulus effects.
France, CP; Ornstein, P; Woods, JH, 1989
)
0.28
" Two potent, selective and competitive NMDA antagonists, cis-4-(phosphonomethyl)-2-piperidine-carboxylic acid (CGS 19755) and 4-(3-phosphonopropyl)-2-piperazine-carboxylic acid (CPP), were characterized in the gerbil ischemia model with respect to dose-response and time course effects."( The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils.
Boast, CA; Etienne, PE; Gerhardt, SC; Lehmann, J; Liebman, JM; Pastor, G, 1988
)
0.27
" The dose-response for in vitro neuroprotection against both NMDA toxicity and combined oxygen-glucose deprivation (OGD) was determined in murine neocortical cultures."( Correlation of CGS 19755 neuroprotection against in vitro excitotoxicity and focal cerebral ischemia.
Giffard, RG; Maier, CM; Pérez-Pinzón, MA; Steinberg, GK; Sun, GH; Yoon, EJ, 1995
)
0.29
") caused vacuolation in cortical pyramidal neurons in the posterior cingulate cortex four hours after dosing and this dose of CGP 37849 caused a pattern of limbic glucose metabolism activation similar to that seen after dizocilpine."( Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism.
Hargreaves, RJ; Hill, RG; Iversen, LL; Rigby, M; Smith, D, 1993
)
0.29
" The dosage was escalated during the study from 1 mg/kg to 6 mg/kg."( First observations of the safety and tolerability of a competitive antagonist to the glutamate NMDA receptor (CGS 19755) in patients with severe head injury.
Bullock, R; Stewart, L; Teasdale, GM; Wagstaff, A, 1999
)
0.3
" However, after chronic daily dosing of 1, 3, or 5 weeks, haloperidol does prevent NRHypo neurotoxicity with longer durations producing greater protection."( Acute D2/D3 dopaminergic agonism but chronic D2/D3 antagonism prevents NMDA antagonist neurotoxicity.
Farber, NB; Nemmers, B; Noguchi, KK, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
TDP1 proteinHomo sapiens (human)Potency0.37590.000811.382244.6684AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)Ki100.00000.00000.41052.7800AID92947
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)9.70550.00071.600310.0000AID143072; AID144462; AID144613; AID144614; AID144621; AID144755; AID144766; AID144892; AID145030; AID145032; AID145097; AID145098; AID566257
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki0.43000.00030.86666.6900AID143146; AID143903; AID145327
Glutamate receptor 1Homo sapiens (human)IC50 (µMol)0.96700.01901.70836.5100AID255256
Glutamate receptor 2Homo sapiens (human)IC50 (µMol)0.96700.01901.64035.5000AID255256
Glutamate receptor 3Homo sapiens (human)IC50 (µMol)0.96700.01901.13424.8000AID255256
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)Ki100.00000.00380.79754.1000AID91469
Glutamate receptor 4Homo sapiens (human)IC50 (µMol)0.96700.01901.22234.8000AID255256
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)8.47370.00071.630610.0000AID143072; AID144462; AID144613; AID144614; AID144621; AID144755; AID144766; AID144892; AID145030; AID145032; AID145097; AID145098; AID241940; AID241941; AID566257
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki0.43000.00030.68056.6900AID143146; AID143903; AID145327
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)9.70550.00061.525710.0000AID143072; AID144462; AID144613; AID144614; AID144621; AID144755; AID144766; AID144892; AID145030; AID145032; AID145097; AID145098; AID566257
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki0.43000.00030.70716.6900AID143146; AID143903; AID145327
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)9.70550.00071.747210.0000AID143072; AID144462; AID144613; AID144614; AID144621; AID144755; AID144766; AID144892; AID145030; AID145032; AID145097; AID145098; AID566257
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki0.43000.00030.81966.6900AID143146; AID143903; AID145327
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)9.70550.00071.741110.0000AID143072; AID144462; AID144613; AID144614; AID144621; AID144755; AID144766; AID144892; AID145030; AID145032; AID145097; AID145098; AID566257
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki0.43000.00030.70726.6900AID143146; AID143903; AID145327
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)9.70550.00071.741110.0000AID143072; AID144462; AID144613; AID144614; AID144621; AID144755; AID144766; AID144892; AID145030; AID145032; AID145097; AID145098; AID566257
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Ki0.43000.00030.70726.6900AID143146; AID143903; AID145327
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)9.70550.00071.741110.0000AID143072; AID144462; AID144613; AID144614; AID144621; AID144755; AID144766; AID144892; AID145030; AID145032; AID145097; AID145098; AID566257
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Ki0.43000.00030.70726.6900AID143146; AID143903; AID145327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
regulation of receptor recyclingGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synapse assemblyGlutamate receptor 1Homo sapiens (human)
long-term memoryGlutamate receptor 1Homo sapiens (human)
response to xenobiotic stimulusGlutamate receptor 1Homo sapiens (human)
response to lithium ionGlutamate receptor 1Homo sapiens (human)
positive regulation of gene expressionGlutamate receptor 1Homo sapiens (human)
neuronal action potentialGlutamate receptor 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 1Homo sapiens (human)
spinal cord developmentGlutamate receptor 1Homo sapiens (human)
cerebral cortex developmentGlutamate receptor 1Homo sapiens (human)
receptor internalizationGlutamate receptor 1Homo sapiens (human)
response to estradiolGlutamate receptor 1Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 1Homo sapiens (human)
response to cocaineGlutamate receptor 1Homo sapiens (human)
positive regulation of membrane potentialGlutamate receptor 1Homo sapiens (human)
response to arsenic-containing substanceGlutamate receptor 1Homo sapiens (human)
response to electrical stimulusGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 1Homo sapiens (human)
long-term synaptic depressionGlutamate receptor 1Homo sapiens (human)
response to fungicideGlutamate receptor 1Homo sapiens (human)
cellular response to amino acid stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to ammonium ionGlutamate receptor 1Homo sapiens (human)
cellular response to dsRNAGlutamate receptor 1Homo sapiens (human)
cellular response to peptide hormone stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to amine stimulusGlutamate receptor 1Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusGlutamate receptor 1Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 2Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 2Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 2Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor 2Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 3Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 3Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
protein homotetramerizationGlutamate receptor 3Homo sapiens (human)
protein heterotetramerizationGlutamate receptor 3Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 3Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 3Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 3Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 4Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processGlutamate receptor 4Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 4Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
amyloid-beta bindingGlutamate receptor 1Homo sapiens (human)
G-protein alpha-subunit bindingGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
protein bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
adenylate cyclase bindingGlutamate receptor 1Homo sapiens (human)
immunoglobulin bindingGlutamate receptor 1Homo sapiens (human)
protein kinase bindingGlutamate receptor 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 1Homo sapiens (human)
PDZ domain bindingGlutamate receptor 1Homo sapiens (human)
small GTPase bindingGlutamate receptor 1Homo sapiens (human)
myosin V bindingGlutamate receptor 1Homo sapiens (human)
G-protein beta-subunit bindingGlutamate receptor 1Homo sapiens (human)
beta-2 adrenergic receptor bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor bindingGlutamate receptor 1Homo sapiens (human)
identical protein bindingGlutamate receptor 1Homo sapiens (human)
protein kinase A bindingGlutamate receptor 1Homo sapiens (human)
scaffold protein bindingGlutamate receptor 1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 2Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
protein bindingGlutamate receptor 2Homo sapiens (human)
ligand-gated monoatomic cation channel activityGlutamate receptor 2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 3Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 3Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 3Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 4Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 4Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
cell-cell junctionGlutamate receptor 1Homo sapiens (human)
cell surfaceGlutamate receptor 1Homo sapiens (human)
ER to Golgi transport vesicle membraneGlutamate receptor 1Homo sapiens (human)
postsynaptic densityGlutamate receptor 1Homo sapiens (human)
dendriteGlutamate receptor 1Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 1Homo sapiens (human)
synaptic vesicle membraneGlutamate receptor 1Homo sapiens (human)
neuromuscular junctionGlutamate receptor 1Homo sapiens (human)
early endosome membraneGlutamate receptor 1Homo sapiens (human)
dendritic spine membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell body membraneGlutamate receptor 1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell bodyGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
dendritic shaftGlutamate receptor 1Homo sapiens (human)
axonal spineGlutamate receptor 1Homo sapiens (human)
neuron spineGlutamate receptor 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor 1Homo sapiens (human)
presynaptic active zone membraneGlutamate receptor 1Homo sapiens (human)
recycling endosomeGlutamate receptor 1Homo sapiens (human)
recycling endosome membraneGlutamate receptor 1Homo sapiens (human)
excitatory synapseGlutamate receptor 1Homo sapiens (human)
synaptic membraneGlutamate receptor 1Homo sapiens (human)
presynapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
glutamatergic synapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density, intracellular componentGlutamate receptor 1Homo sapiens (human)
perisynaptic spaceGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
external side of plasma membraneGlutamate receptor 2Homo sapiens (human)
postsynaptic densityGlutamate receptor 2Homo sapiens (human)
dendriteGlutamate receptor 2Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 2Homo sapiens (human)
asymmetric synapseGlutamate receptor 2Homo sapiens (human)
neuronal cell bodyGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
excitatory synapseGlutamate receptor 2Homo sapiens (human)
postsynapseGlutamate receptor 2Homo sapiens (human)
postsynaptic endocytic zoneGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic membraneGlutamate receptor 3Homo sapiens (human)
parallel fiber to Purkinje cell synapseGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 3Homo sapiens (human)
dendritic spineGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendriteGlutamate receptor 4Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 4Homo sapiens (human)
neuronal cell bodyGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
extracellular vesicleGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 4Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 4Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay IDTitleYearJournalArticle
AID74396Concentration required to inhibit glucosamine-6-phosphate synthase (GFAT) isolated from Candida albicans2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Multisubstrate analogue inhibitors of glucosamine-6-phosphate synthase from Candida albicans.
AID185187Tested for antagonism of NMDA induced convulsions in neonatal rats (ip) and minimum effective dose (MED) was reported1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action.
AID180480Percent inhibition of glutamate activity against cGMP was determined1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.
AID144621Inhibition of N-methyl-D-aspartate glutamate receptor by using [3H]CPP as a radioligand from the rat cortical membranes.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
New and versatile approaches to the synthesis of CPP-related competitive NMDA antagonists. Preliminary structure-activity relationships and pharmacological evaluation.
AID144613In vitro binding affinity against N-methyl-D-aspartate glutamate receptor using [3H]CGS-19,755 ligand1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action.
AID144457Ability to displace [3H]CPP from NMDA receptor in rat brain membrane1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists.
AID144766In vitro compound's ability to displace [3H]-CGS-19,755 binding as a measure of its affinity for the glutamate recognition site on the NMDA receptor complex.1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists.
AID143903Compound was evaluated for its ability to displace [3H]CPP or [3H]-CGS- 19755 ligand from N-methyl-D-aspartate (NMDA) receptor1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Modeling of competitive phosphono amino acid NMDA receptor antagonists.
AID115599Ability to protect against NMDA-induced lethality in mice after intraperitoneal administration1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and pharmacology of a series of 3- and 4-(phosphonoalkyl)pyridine- and -piperidine-2-carboxylic acids. Potent N-methyl-D-aspartate receptor antagonists.
AID145097Tested for binding affinity against NMDA receptor, from rat synaptic membrane, using [3H]-CPP as the radioligand.1993Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3
Potent quinoxaline-spaced phosphono alpha-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation.
AID566257Inhibition of rat NMDA receptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID145327Compound was tested in vitro for N-methyl-D-aspartate glutamate receptor binding using [3H]L-glutamate1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological evaluation of cyclopropyl analogues of 2-amino-5-phosphonopentanoic acid.
AID132435Functional NMDA antagonist activity was confirmed in vivo in mice (intraperitoneally) using an NMDA-induced lethality assay2001Journal of medicinal chemistry, May-10, Volume: 44, Issue:10
Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-alpha-amino acid competitive NMDA antagonists of the AP-6 type.
AID91469Binding affinity towards Ionotropic glutamate receptor kainate using [3H]-kainic acid as radioligand; Inactive1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.
AID241940Inhibition of [3H]CPP binding to rat N-methyl-D-aspartic acid receptor 2A2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Development of a three-dimensional model for the N-methyl-D-aspartate NR2A subunit.
AID133115Tested for antagonism of NMDA induced lethality in neonatal mice (ip) and minimum effective dose (MED) was reported1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action.
AID112373Tested in vivo for inhibition of NMDA induced lethality, in male Swiss-Albino mice after ip administration.1993Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3
Potent quinoxaline-spaced phosphono alpha-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation.
AID145098Tested for binding affinity against NMDA receptor, from rat synaptic membrane, using [3H]TCP as the radioligand.1993Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3
Potent quinoxaline-spaced phosphono alpha-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation.
AID147421Compound was tested in vitro for Non N-methyl-D-aspartate glutamate receptor binding using [3H]kainate1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological evaluation of cyclopropyl analogues of 2-amino-5-phosphonopentanoic acid.
AID143146Compound was evaluated for its ability to displace [3H]CPP or [3H]-CGS- 19755 ligand from N-methyl-D-aspartate (NMDA) receptor1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Modeling of competitive phosphono amino acid NMDA receptor antagonists.
AID255256Percent inhibition against AMPA receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID133101Minimum effective dose measures the in vivo NMDA antagonist activity of compound and its ability to protect mice from lethality induced by 200 mg/kg ip injection of NMDA.1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID114180Effective dose against NMDA-induced lethality in mice on ip administration1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere.
AID92947Binding affinity towards AMPA receptor using [3H]AMPA as radioligand; Inactive1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.
AID144892Inhibition of [3H]-CGS- 19755 binding to N-methyl-D-aspartic acid receptors in rat crude synaptic membranes1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity.
AID144460Affinity for the NMDA receptor site was assessed by its ability to displace [3H]TCP from its binding site in rat brain2001Journal of medicinal chemistry, May-10, Volume: 44, Issue:10
Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-alpha-amino acid competitive NMDA antagonists of the AP-6 type.
AID114702Effective dose of the intraperitoneally administered compound causing loss of traction reflex, was tested in N-methyl-D-aspartic acid convulsions model1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity.
AID144614Compound was evaluated in vitro in a cortical-wedge preparation for the antagonism of N-methyl-D-aspartate-induced responses1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID143309In vitro binding affinity towards N-methyl-D-aspartate glutamate receptor of the glutamate receptor using [3H]CPP as radioligand in rat cerebral cortical membranes.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.
AID145032Displacement of [3H]CPP from rat brain synaptic membrane N-methyl-D-aspartate glutamate receptor1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere.
AID241941Inhibition of [3H]Glu binding to rat N-methyl-D-aspartic acid receptor 2A2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Development of a three-dimensional model for the N-methyl-D-aspartate NR2A subunit.
AID144755Compound was tested in vitro for its inhibitory activity against N-methyl-D-aspartate glutamate receptor using [3H]MK-8011991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and biological evaluation of cyclopropyl analogues of 2-amino-5-phosphonopentanoic acid.
AID144332Binding affinity for glutamate-stimulated TCP binding site of N-methyl-D-aspartate glutamate receptor from rat brain by using [3H]TCP as radioligand; Antagonist1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
New and versatile approaches to the synthesis of CPP-related competitive NMDA antagonists. Preliminary structure-activity relationships and pharmacological evaluation.
AID114705Effective dose of the intraperitoneally administered compound protecting mice against tonic seizures, was tested in N-methyl-D-aspartic acid convulsions model1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity.
AID145030Tested in vitro for antagonistic activity at N-methyl-D-aspartate glutamate receptor by measuring displacement of [3H]TCP from crude synaptic membrane preparations obtained from rat brain1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere.
AID144057Compound was evaluated for the inhibition of the binding of [3H]-CPP against NMDA receptor in mice1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and pharmacology of a series of 3- and 4-(phosphonoalkyl)pyridine- and -piperidine-2-carboxylic acids. Potent N-methyl-D-aspartate receptor antagonists.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID143072Tested for binding affinity against NMDA receptor, from rat synaptic membrane, using [3H]glycine as the radioligand.1993Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3
Potent quinoxaline-spaced phosphono alpha-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation.
AID132864In vitro inhibition of 40 uM NMDA induced depolarization in mouse cortical slices.1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists.
AID144462Displacement of [3H]CPP from rat synaptic membrane glutamate NMDA receptor2001Journal of medicinal chemistry, May-10, Volume: 44, Issue:10
Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-alpha-amino acid competitive NMDA antagonists of the AP-6 type.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (243)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (5.35)18.7374
1990's180 (74.07)18.2507
2000's39 (16.05)29.6817
2010's8 (3.29)24.3611
2020's3 (1.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.73 (24.57)
Research Supply Index5.56 (2.92)
Research Growth Index5.62 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (3.60%)5.53%
Reviews7 (2.80%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other234 (93.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]